drugset / Trial / NCT06444022
hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
Phase 1
Withdrawn
Nanfang Hospital, Southern Medical University
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is a parallel controlled clinical study evaluating the safety and efficacy of hAECs in preventing aGVHD after HSCT.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Outcome
Outcome not reported
Stopped: “The research content involving the use of hAESCs for the prevention of aGVHD after HSCT has completed the IND application for treating the said condition. Therefore, an application is submitted to terminate this research project.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Amniotic Epithelial Stem Cells | Unknown | 1e+06 cells/kg | Intravenous |